Volume : 09, Issue : 04, April – 2022
Title:
44.DRUG REPURPOSING (DR) APPROACHES AND CHALLENGES IN CURRENT PANDEMIC: A REVIEW
Authors :
Aditi Gupta, Aakib Ali, Abhijeet K. Lodhi, Abhishal Awasthi, Sonika Jain, Dr. Vivek Jain
Abstract :
Traditional drug development and discovery has not kept pace with threats from emerging and re-emerging diseases such as Ebola virus, MERS-CoV and more recently, SARS-CoV-2. Among other reasons, the exorbitant costs, high attrition rate and extensive periods of time from research to market approval are the primary contributing factors to the lag in recent traditional drug developmental activities. The improving knowledge of the virology and clinical presentation of COVID-19 is leading to a broadening pool of potential pharmacological targets. The aim of this review is to describe regulatory and pharmacological aspects of drug repurposing and to identify drugs proposed for repurposing in COVID-19 based on registered clinical trials, Model-informed drug repurposing, Drug repurposing, Drug repurposing for COVID-19 , Proposed AI techniques for drug Repurposing . The challenges of the correct interpretation of existing pre-clinical/clinical evidence as well as the Proposed AI techniques for drug Repurposing will also be discussed.
Key words: Drug repurposing, COVID-19, Challenges, Approaches
Cite This Article:
Please cite this article in press Vivek Jain et al, Drug Repurposing (Dr) Approaches And Challenges In Current Pandemic: A Review., Indo Am. J. P. Sci, 2022; 09(04).,
Number of Downloads : 10
References:
1. Wang L, Wang Y, Ye D, Liu Q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. International journal of antimicrobial agents 2020;55 (6):105948
2. Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. International journal of biological sciences 2018;14(10):1232-44
3. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1): 41-58.
4. Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012;17(9–10):419-424
5. Baker EH, Gnjidic D, Kirkpatrick CMJ, Pirmohamed M, Wright DFB, Zecharia AY. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments. Br J Clin Pharmacol. 2020.
6. Canini L, Carrat F. Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol. 2011;85(6):2764-2770.
7. Ferguson N, Cummings D, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005;437:209-214.
8. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, DeVincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011; 204(7):996-1002.
9. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
10. Zhou B, She J, Wang Y, Ma X. Duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis. 2020;71 (16):2240-2242.
11. Nicholson KG, Aoki FY, Osterhaus A, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet. 2000;355(9218):1845-1850.
12. DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373(21):2048-2058.
13. Dodd LE, Follmann D, Wang J, et al. Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clin Trials. 2020;17(5): 472-482.
14. Ngo H, Garneau T, Sylvie G, D. K. A complex game of hide and seek: the search for new antifungals. MedChemComm 2016;7(7):1285-306.
15. Rolain J, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International journal of antimicrobial agents 2007;30(4):297-308.
16. Chan J, Yao Y, Yeung M, Deng W, Bao L, Jia L. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. The Journal of infectious diseases 2015;212(12):1904-13.
17. Mohs R, Greig N. Drug discovery and development: Role of basic biological research. Alzheimer’s Dementia: Translational Research Clinical Interventions 2017;3(4):651-7.
18. GNS H, Saraswathy G, Murahari M, Krishnamurthy M. An update on drug repurposing: re-written saga of the drug’s fate. Biomedicine Pharmacotherapy 2019;110(2):700-16.
19. Mak K, Pichika M. Artificial intelligence in drug development: present status and future prospects. Drug discovery today 2019;24(3):773-80.
20. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 2020;6(14):1-18.
21. J K. How Will Big Data Analytics Factor into the Next Phase of COVID-19? Health it analytics 2020:https://healthitanalytics.com/news/how-will-big-dataanalytics-factor-into-the-next-phase-of-covid-19.
22. A S. How AI is fighting COVID-19: the companies using intelligent tech to find new drugs,. Pharmaphorum 2020:https://pharmaphorum.com/views-analysisdigital/how-ai-is-fighting-covid-19-the-companies-using-intelligent-tech-to-findnew-drugs.
23. 23.Sams-Dodd, F. (2005). Target-based drug discovery: Is something wrong? Drug Discovery Today 10, 139–147.
24. Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., … Qin, C. (2020). The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830–833
25. Zheng, J., Wong, L. R., Li, K., Verma, A. K., Ortiz, M. E., Wohlford-Lenane, C., … Perlman, S. (2021). COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603–607